These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34213395)

  • 21. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
    Kanevsky I; Surendran N; McElwee K; Lei L; Watson W; Pride M; Scully I; Karauzum H; Anderson A; Young M
    Vaccine; 2023 Oct; 41(45):6625-6629. PubMed ID: 37793976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
    Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
    Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
    Buchwald UK; Andrews CP; Ervin J; Peterson JT; Tamms GM; Krupa D; Ajiboye P; Roalfe L; Krick AL; Sterling TM; Wang M; Martin JC; Stek JE; Kohn MA; Folaranmi T; Abeygunawardana C; Hartzel J; Musey LK;
    Hum Vaccin Immunother; 2021 Aug; 17(8):2678-2690. PubMed ID: 34019468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C.
    Shi Y; Nolan KM; Burton RL; Shekar T; Murphy RD; Banniettis N; Musey L; Buchwald UK
    Hum Vaccin Immunother; 2023 Aug; 19(2):2235238. PubMed ID: 37529944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; El Sahly HM; George S; Winokur P; Edwards K; Brady RC; Rouphael N; Keitel WA; Mulligan MJ; Burton RL; Nakamura A; Ferreria J; Nahm MH
    Vaccine; 2018 Jan; 36(5):606-614. PubMed ID: 29279281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
    Azuma M; Oishi K; Akeda Y; Morino S; Motoki Y; Hanibuchi M; Nishioka Y
    Vaccine; 2023 Jan; 41(5):1042-1049. PubMed ID: 36593171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients.
    Oesterreich S; Lindemann M; Goldblatt D; Horn PA; Wilde B; Witzke O
    Vaccine; 2020 Apr; 38(17):3339-3350. PubMed ID: 32178906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
    Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
    Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors.
    Takeshita K; Ishiwada N; Takeuchi N; Ohkusu M; Ohata M; Hino M; Hishiki H; Takeda Y; Sakaida E; Takahashi Y; Shimojo N; Hamada H
    Vaccine; 2022 Feb; 40(9):1238-1245. PubMed ID: 35125220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
    Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
    Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in non pneumococcal conjugate vaccine immunized healthy Japanese and intravenous immunoglobulin preparations.
    Takahashi Y; Ishiwada N; Hishiki H; Tanaka J; Akeda Y; Shimojo N; Oishi K; Kohno Y
    J Infect Chemother; 2014 Dec; 20(12):794-8. PubMed ID: 25242584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
    Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
    Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
    Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
    Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
    Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.